Published • loading... • Updated
New GLP-1 Drugs Could Suppress Desire for More than Just Food, Study Suggests
Researchers found oral GLP-1 drugs also dampen reward-driven eating by activating the central amygdala and reducing dopamine release in mice.
- On May 6, 2026, National Institutes of Health -funded researchers published a study in Nature showing oral GLP-1 weight-loss drugs modulate a brain reward circuit in mice.
- Earlier studies focused on larger peptide-based GLP-1s targeting hunger-regulating networks, so researchers at the University of Virginia investigated newer small-molecule oral medications.
- Researchers identified that these drugs triggered activity in the central amygdala, and Ali Guler, a professor of biology at Virginia, said drugs "dial back eating for pleasure by engaging a brain reward circuit."
- Findings suggest small-molecule GLP-1s could treat substance use disorder and binge-eating; Lorenzo Leggio, clinical director of NIH, said "it's crucial that we understand the neural mechanisms underlying the effects."
- Because the study was not a clinical trial assessed by the FDA, scientists plan follow-up research to examine how these drugs affect substance use disorder.
Insights by Ground AI
13 Articles
13 Articles
GLP-1 weight-loss drugs modulate brain reward circuits to suppress eating for pleasure
A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight-loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain.
·United States
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left0Leaning Right0Center13Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
